TYRA Reports $383.5M Cash, Advances Dabogratinib 3x3 Strategy in Q1 2026
Tyra Biosciences, Inc. Common Stock · PHARMACEUTICAL PREPARATIONS · Now $30.39
-10% in 7d after detection
Post-detection moves
1h
—
1d
+0.9%
3d
-1.5%
7d
-10%
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS